Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) shares were down 6.9% during mid-day trading on Wednesday . The stock traded as low as $144.76 and last traded at $144.76. Approximately 24,936 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 54,921 shares. The stock had previously closed at $155.47.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Mesa Laboratories in a research report on Thursday, May 18th. They set a “hold” rating for the company.
Mesa Laboratories Stock Down 2.0 %
The business has a 50-day moving average price of $166.41 and a two-hundred day moving average price of $173.37. The company has a current ratio of 2.74, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49.
Mesa Laboratories Dividend Announcement
Insider Transactions at Mesa Laboratories
In other news, CFO John Sakys sold 2,128 shares of the business’s stock in a transaction on Friday, March 24th. The stock was sold at an average price of $167.01, for a total transaction of $355,397.28. Following the completion of the transaction, the chief financial officer now owns 9,696 shares of the company’s stock, valued at approximately $1,619,328.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders sold 6,028 shares of company stock valued at $1,018,145. Corporate insiders own 5.50% of the company’s stock.
Hedge Funds Weigh In On Mesa Laboratories
A number of institutional investors and hedge funds have recently bought and sold shares of MLAB. Morgan Stanley increased its holdings in Mesa Laboratories by 808.7% in the 4th quarter. Morgan Stanley now owns 263,735 shares of the medical instruments supplier’s stock worth $43,835,000 after purchasing an additional 234,712 shares in the last quarter. Geneva Capital Management LLC increased its holdings in Mesa Laboratories by 83.1% in the 4th quarter. Geneva Capital Management LLC now owns 191,816 shares of the medical instruments supplier’s stock worth $31,882,000 after purchasing an additional 87,031 shares in the last quarter. Conestoga Capital Advisors LLC increased its holdings in Mesa Laboratories by 17.8% in the 4th quarter. Conestoga Capital Advisors LLC now owns 574,783 shares of the medical instruments supplier’s stock worth $95,535,000 after purchasing an additional 86,648 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of Mesa Laboratories by 115.8% in the fourth quarter. Point72 Asset Management L.P. now owns 78,014 shares of the medical instruments supplier’s stock valued at $12,967,000 after buying an additional 41,855 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in shares of Mesa Laboratories by 36.2% in the first quarter. Dimensional Fund Advisors LP now owns 106,812 shares of the medical instruments supplier’s stock valued at $18,663,000 after buying an additional 28,386 shares during the period. Institutional investors and hedge funds own 93.00% of the company’s stock.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development.
- Get a free copy of the StockNews.com research report on Mesa Laboratories (MLAB)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.